Stockscreener 앱 받기
4.495
4.96%
-0.245
전일 마감가:
$4.74
열려 있는:
$4.62
하루 거래량:
4.18M
Relative Volume:
0.72
시가총액:
$1.54B
수익:
$26.75M
순이익/손실:
$-217.48M
주가수익비율:
-7.0212
EPS:
-0.6402
순현금흐름:
$-198.25M
1주 성능:
-22.33%
1개월 성능:
-19.84%
6개월 성능:
+15.51%
1년 성능:
+140.91%
1일 변동 폭
$4.45
$4.73
1주일 범위
$4.16
$5.92
52주 변동 폭
$1.54
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
명칭
Nuvation Bio Inc
전화
332-208-6102
주소
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
4.50 | 1.63B | 26.75M | -217.48M | -198.25M | -0.6402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.98 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.08 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.22 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.13 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-19 | 개시 | B. Riley Securities | Buy |
| 2025-09-30 | 개시 | Jefferies | Buy |
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-03-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-03-26 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-01-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-05-04 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-04-06 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 개시 | BMO Capital Markets | Outperform |
| 2021-03-08 | 개시 | BTIG Research | Buy |
| 2021-03-08 | 개시 | Cowen | Outperform |
| 2021-03-08 | 개시 | Jefferies | Buy |
| 2021-03-08 | 개시 | Wedbush | Outperform |
모두보기
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
Nuvation Bio Hits Day High with Strong 8.72% Intraday Surge - Markets Mojo
Q1 EPS Estimates for Nuvation Bio Reduced by HC Wainwright - MarketBeat
Nuvation Bio (NUVB) Q4 2025 Earnings Transcript - AOL.com
Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch - Bitget
NUVB: First-line patient growth, strong efficacy, and robust cash position drive positive outlook - TradingView
Nuvation Bio Inc. (NYSE:NUVB) Q4 2025 Earnings Call Transcript - Insider Monkey
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out - GlobeNewswire
Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress - Yahoo Finance
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Nuvation Bio Inc. $NUVB is Aisling Capital Management LP's 4th Largest Position - MarketBeat
NUVB-WT Nuvation Bio NYSE down 27% pre-market after Q4: cash runway focus - Meyka
Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks - TipRanks
Nuvation Bio (NUVB) awards stock options and RSUs to company officer - Stock Titan
Director Xiangmin Cui awarded 74,813 Nuvation Bio (NUVB) stock options - Stock Titan
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy - The Globe and Mail
Deep Dive Into Nuvation Bio Stock: Analyst Perspectives (7 Ratings) - Benzinga
UBS Group Lowers Nuvation Bio (NYSE:NUVB) Price Target to $7.00 - MarketBeat
Nuvation Bio (NUVB) Analyst Rating Update: UBS Lowers Price Targ - GuruFocus
NUVB Crosses Below Key Moving Average Level - Nasdaq
Nuvation Bio (NYSE:NUVB) Shares Gap DownShould You Sell? - MarketBeat
NUVB: RBC Capital Raises Price Target for Nuvation Bio | NUVB St - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Nuvation Bio (NYSE:NUVB) Stock - MarketBeat
UBS Adjusts Price Target on Nuvation Bio to $7 From $10, Maintains Neutral Rating - marketscreener.com
Nuvation Bio price target raised to $13 from $12 at RBC Capital - TipRanks
RBC Raises Price Target on Nuvation Bio to $13 From $12, Keeps Outperform, Speculative Risk - marketscreener.com
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch By Investing.com - Investing.com UK
Nuvation Bio Posts Narrower FY25 Loss, Highlights IBTROZI Launch And Pipeline Progress; Stock Down - Nasdaq
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch - Investing.com
Nuvation Bio Q4 2025 Earnings Call Transcript - MarketBeat
Nuvation Bio Q4 Earnings Call Highlights - MarketBeat
Nuvation Bio reports Q4 EPS (11c), consensus (5c) - TipRanks
Earnings call transcript: Nuvation Bio Q4 2025 sees revenue beat, stock dips - Investing.com
Earnings call transcript: Nuvation Bio Q4 2025 sees revenue beat, stock dips By Investing.com - Investing.com South Africa
Nuvation Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Why Nuvation Bio Stock Is Dropping Despite Analyst Hikes - TipRanks
Nuvation Bio Inc. (NUVB) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
Nuvation Bio (NYSE:NUVB) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
Nuvation Bio Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:NUVB) 2026-03-02 - Seeking Alpha
Nuvation Bio (NUVB) launches IBTROZI and advances safusidenib, global partnerships - Stock Titan
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Nuvation Bio Q4 Loss Narrows, Revenue Rises - marketscreener.com
Earnings Flash (NUVB) Nuvation Bio Posts Q4 Loss $-0.11, vs. FactSet Est of Loss of $-0.09 - marketscreener.com
IBTROZI launch lifts Nuvation Bio (NUVB) 2025 revenue while losses narrow - Stock Titan
NUVB: Rapid IBTROZI uptake, Eisai partnership, and improved net loss highlight Q4 2025 results - TradingView
Earnings Flash (NUVB) Nuvation Bio Inc. Reports Q4 Revenue $41.9M, vs. FactSet Est of $37.8M - marketscreener.com
Earnings Breakdown: Nuvation Bio Q4 - Benzinga
Nuvation Bio earnings in focus: Ibtrozi momentum faces test - Investing.com UK
Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma - Finviz
Nuvation Bio Expands SIGMA Study to Phase 3 Trial - Intellectia AI
Nuvation Bio (NUVB) Is Up 8.6% After Expanding Safusidenib Into Phase 3 Registrational TrialHas The Bull Case Changed? - Yahoo Finance
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Nuvation Bio Inc (NUVB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.35%
자본화:
|
볼륨(24시간):